Suppression of Ovarian Function Trial (SOFT)

  • In the Suppression of Ovarian Function Trial (SOFT) trial:
    • Ovarian function suppression given for 5 years reduced disease-free survival (DFS) events when added to 5 years of adjuvant tamoxifen:
      • 78.9% to 83.2% DFS at 8 years, hazard ratio (HR) of 0.76, P = .009)
    • One-third of women entered in the SOFT trial:
      • Were randomized to receive the aromatase inhibitor exemestane plus ovarian function suppression and they had an even better disease-free survival


1. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Eng J Med.2018;379(2):122-137.

2. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s